The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a ...

Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...

U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), ...

Tanabe Pharma focuses on therapeutic areas such as immunology and inflammation, vaccines, diabetes, and central nervous ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), ...

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

Bain Capital is nearing a deal to buy Mitsubishi Chemical Group Corp.’s pharmaceutical unit, people familiar with the matter ...

Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

Bain Capital has agreed to acquire Mitsubishi Chemical Group’s4188-4.18%decrease; red down pointing triangle pharmaceutical business for more than $3 billion, a deal that would allow the ...